Rongchang Pharmaceutical describes new Menin/KMT2A interaction inhibitors
Rongchang Pharmaceutical (Zibo) Co. Ltd. has patented new Menin (MEN1)/KMT2A (MLL) interaction inhibitors designed for use in the treatment of cancer.
Rongchang Pharmaceutical (Zibo) Co. Ltd. has patented new Menin (MEN1)/KMT2A (MLL) interaction inhibitors designed for use in the treatment of cancer.